Prescient Therapeutics (ASX: PTX)

Prescient Therapeutics Ltd. is a biopharmaceutical company. The company is headquartered in South Melbourne, Victoria. The company is also focused on developing therapies for a range of cancers, using CAR-T and targeted therapy approaches. The firm has a broad pipeline of cancer treatments, comprising CAR-T and targeted therapies, for cancers. Its product pipeline includes OmniCAR, PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product. PTX-100 is a Phase Ib clinical candidate that block the cancer growth enzyme known as geranylgeranyl transferase-1. PTX-100 is in a pharmacokinetic basket study of hematological and solid malignancies, focusing on cancers with Ras and RhoA mutations. PTX-200 is in Phase Ib/IIa clinical candidate. PTX-200 is a novel PH domain inhibitor that inhibits an important tumor survival pathway known as Akt.

Here are the latest articles on Prescient Therapeutics (ASX: PTX)

The ASX listed biotech companies making their mark in oncology

March 31, 2023

Balance sheets don’t tell the whole story. This is especially true for biotech companies where pre-revenue businesses can still be worth billions of dollars with the innovative medicines they are creating. On a macro level, biotech companies outperformed the S&P 500 and both pharmaceutical and medtech sectors in terms of total returns to shareholders over

Prescient Therapeutics sures supply of cell therapeutic in the hopes of commencing clinical trials

August 16, 2022

During the second World War, scientists noted that soldiers exposed to nitrogen mustard gas developed interesting hematologic pathology with significantly reduced white blood cell counts. Researchers began to wonder if the toxins could stop the growth of rapidly dividing cancer cells. It wasn’t long before American pharmacologists Alfred Gilman and Louis Goodman experimented with mustard

Category Specific RSS